Boston Scientific is writing a $1.5 billion check to muscle back into the structural-heart arena, grabbing roughly a third of MiRus and locking in an exclusive option to buy its balloon-expandable SIEGEL valve business if the younger company clears key clinical and regulatory hurdles. The pact could speed Boston Scientific’s return to a segment it largely stepped away from last year. Company and industry commentary points to the SIEGEL valve’s nickel-free frame and small-sheath delivery as features that may offer a different risk profile for some TAVR patients.
Deal Details
According to Boston Scientific, the company is paying $1.5 billion for an approximately 34% equity stake in MiRus and securing an exclusive option to acquire the MiRus TAVR business by making additional cash payments totaling $3.0 billion, subject to customary closing conditions and milestone achievement. The company said the investment is expected to have an immaterial impact on adjusted earnings per share for 2026.
About the SIEGEL Valve
MiRus describes the SIEGEL system as a nickel-free, balloon-expandable transcatheter aortic valve built on a proprietary rhenium frame, with dry porcine leaflets and an open-cell design that the company says eliminates foreshortening. Industry coverage notes that MiRus has moved from early feasibility work into the STAR pivotal trial, which will enroll up to 1,025 patients to evaluate safety and effectiveness, per MassDevice.
Why This Matters For Boston Scientific
Boston Scientific halted sales of its ACURATE neo2 and ACURATE Prime TAVR systems in May 2025 after regulatory and clinical challenges, effectively stepping back from the balloon-expandable market, according to Cardiac Interventions Today. The MiRus investment follows a heavier slate of strategic dealmaking this year, including the January acquisition of Penumbra, and signals that Boston Scientific is leaning on targeted deals to refill gaps in its structural-heart portfolio, per Bloomberg.
What Comes Next
Boston Scientific says it can exercise its option to acquire the MiRus TAVR business only after MiRus hits defined clinical and regulatory milestones, and that additional payments, along with potential sales-based or valve-asset payments, would be part of the economics if the option is exercised, according to Boston Scientific. Investors and hospital procurement teams are likely to watch STAR trial results and any follow-on regulatory filings closely before they factor in the odds of a full acquisition or broad hospital adoption.
Regulatory And Clinical Landscape
The SIEGEL system remains investigational and is not approved for commercial distribution in any country. Early data are limited, and pivotal outcomes are expected to be determinative, per reporting by Medical Device Network. Clinicians will be focused on valve durability, the likelihood of patients needing pacemakers, and vascular complication rates when they size up SIEGEL against established platforms.
For Boston Scientific, the structure of the deal, invest now and buy later only if milestones validate the technology, amounts to a way to chase innovation while dialing down near-term cash and operational risk. For patients and hospitals, the real verdict will come from the STAR trial and any regulatory clearances that follow, which could still be years away.
